A new instrument to characterize O2 transport by cell-free hemoglobin and/or mixtures of cell-free hemoglobin and red blood cells has been invented, and a patent has been applied for. This instrument measures diffusional O2 transport using a small sample, and is applicable both to the development of cell-free hemoglobin solutions and to monitoring patients who have received them. The goal of this proposal is to optimize the design of this instrument to measure O2 transport by cell-free hemoglobin solutions in vitro using an artificial capillary system.
Under Specific Aim 1, we will build an artificial capillary system to assess O2 transport by cell- free hemoglobin solutions in vitro. We will optimize the breadboard design of our present artificial capillary instrument. Measurements of O2 transport will be made using cell-free hemoglobin solutions, including model solutions of PEG-hemoglobin and cross-linked tetrameric hemoglobin, and RBC suspensions.
Under Specific Aim 2, we will automate the capillary apparatus and further develop software for data interpretation. The data- analysis model uses mathematical concepts based on the Krogh cylinder model for O2 transport out a cylindrical tube of defined geometry (i.e., the artificial capillary). This programs requires 1) optimization for run time efficiency and 2) testing against experimental data from hemoglobin solutions and/or red blood cells in the artificial capillary device. The hypothesis underlying this proposal is that a new method to assess O2 transport by cell-free oxygen carriers is required before candidate products can be evaluated accurately. This is due to the phenomenon of facilitated diffusion of O2 in the presence of cell-free carriers, which can lead to autoregulatory vasoconstriction.

Proposed Commercial Applications

Methods of clinical evaluation of O2 transport (Hb, Het) in the presence of cell-free oxygen carriers are inadequate. We have invented a new instrument to characterize O2 transport by cell-free hemoglobin that includes evaluation of facilitated diffusion. This instrument has great potential for clinical measures in patients who have received hemoglobin- based products, as well as potential in the testing of new candidate solution.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HL063577-01
Application #
6017329
Study Section
Special Emphasis Panel (ZRG1-CVB (02))
Project Start
1999-08-01
Project End
2000-01-31
Budget Start
1999-08-01
Budget End
2000-01-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Sangart, Inc.
Department
Type
DUNS #
158586706
City
San Diego
State
CA
Country
United States
Zip Code
92121